Rezaei Hessam, Asefnejad Azadeh, Daliri-Joupari Morteza, Joughehdoust Sedigheh
Department of Biomedical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Prog Biomater. 2021 Jun;10(2):161-171. doi: 10.1007/s40204-021-00160-9. Epub 2021 Jun 24.
Urinary incontinence is one of the most common disorders especially in adult women. In this study, cellular and in-vivo analyses were performed on (3-glycidyloxypropyl) trimethoxysilane (GPTMS) and CaCl cross-linked alginate and gelatin hydrogels containing β-glycerophosphate and ascorbic acid to evaluate the regenerative potential as injectable compression agents for the treatment of urinary incontinence. The hydrogels were prepared with different percentages of components and were named as GA1 (7.2% w/v gelatin, 6% w/v sodium alginate, 0.5:1w/w GPTMS, CaCl 1% (wt) sodium alginate, 50 μg/mL ascorbic acid, 1.5 mg/mL β-glycerophosphate), GA2 (10% w/v gelatin, 8.5% w/v sodium alginate, 0.5:1 w/w GPTMS, CaCl 1% (wt) sodium alginate, 50 μg/mL ascorbic acid, 1.5 mg/mL β-glycerophosphate), and GA3 (10% (w/v) gelatin, 8.5% w/v sodium alginate, 1:1 w/w GPTMS, CaCl 1% (wt) sodium alginate, 50 μg/mL ascorbic acid, 1.5 mg/mL β-glycerophosphate) hydrogels. The results of cell studies showed that although all three samples supported cell adhesion and survival, the cellular behavior of the GA2 sample was better than the other samples. Animal tests were performed on the optimal GA2 sample, which showed that this hydrogel repaired the misfunction tissue in a rat model within 4 weeks and the molecular layer thickness was reached the normal tissue after this duration. It seems that these hydrogels, especially GA2 sample containing 10% (w/v) gelatin, 8.5% (w/v) sodium alginate, 0.5:1 (w/w) GPTMS, CaCl 1% (wt) sodium alginate, 50 μg/mL ascorbic acid, and 1.5 mg/mL β-glycerophosphate, can act as an injetable hydrogel for urinary incontinence treatment without the need for repeating the injection.
尿失禁是最常见的病症之一，在成年女性中尤为如此。在本研究中，对（3-缩水甘油氧基丙基）三甲氧基硅烷（GPTMS）以及含有β-甘油磷酸酯和抗坏血酸的氯化钙交联海藻酸钠和明胶水凝胶进行了细胞和体内分析，以评估其作为可注射压迫剂治疗尿失禁的再生潜力。制备了不同成分百分比的水凝胶，并将其命名为GA1（7.2% w/v明胶、6% w/v海藻酸钠、0.5:1 w/w GPTMS、1% (wt)海藻酸钠的氯化钙、50 μg/mL抗坏血酸、1.5 mg/mLβ-甘油磷酸酯）、GA2（10% w/v明胶、8.5% w/v海藻酸钠、0.5:1 w/w GPTMS、1% (wt)海藻酸钠的氯化钙、50 μg/mL抗坏血酸、1.5 mg/mLβ-甘油磷酸酯）和GA3（10% (w/v)明胶、8.5% w/v海藻酸钠、1:1 w/w GPTMS、1% (wt)海藻酸钠的氯化钙、50 μg/mL抗坏血酸、1.5 mg/mLβ-甘油磷酸酯）水凝胶。细胞研究结果表明，尽管所有三个样品均支持细胞黏附和存活，但GA2样品的细胞行为优于其他样品。对最佳的GA2样品进行了动物试验，结果表明该水凝胶在4周内修复了大鼠模型中的功能失调组织，在此时间段后分子层厚度达到了正常组织水平。似乎这些水凝胶，尤其是含有10% (w/v)明胶、8.5% (w/v)海藻酸钠、0.5:1 (w/w) GPTMS、1% (wt)海藻酸钠的氯化钙、50 μg/mL抗坏血酸和1.5 mg/mLβ-甘油磷酸酯的GA2样品，可以作为一种用于治疗尿失禁的可注射水凝胶，无需重复注射。
